Below is a detailed English introduction to China National Pharmaceutical Group Corporation (Sinopharm), compiled based on the group's official information and authoritative public records:
China National Pharmaceutical Group Corporation, commonly known as Sinopharm, was founded on March 26, 1987, with its headquarters located at 20 Zhichun Road, Haidian District, Beijing. It is the only central enterprise directly managed by the State-owned Assets Supervision and Administration Commission of the State Council that focuses on life and health as its core business. Moreover, it stands as a leading comprehensive medical and health industry group in China and Asia in terms of comprehensive strength and scale, and also serves as a key national medical reserve entity.
Sinopharm has built a complete and integrated industrial chain covering nine major sectors in the health field, forming a full-cycle service system for the whole health industry. The specific business layout is as follows. In the field of scientific research and development, it has strong innovative capabilities and focuses on the research of key areas such as biomedicines and vaccines. As the world's sixth-largest vaccine manufacturer, it supplies 80% of the vaccines required for China's immunization programs. In terms of industrial manufacturing, it covers the production of a wide range of products including chemical drugs, traditional Chinese medicines, biological products and medical devices. Regarding logistics and distribution, it has a large - scale and efficient medical logistics network, ensuring the timely delivery of medical supplies across the country. Its business also extends to retail chains, with a number of pharmacy stores providing convenient medical and health products and services for the public. Additionally, it involves businesses like medical and health care, engineering technology, professional exhibitions, international operations and financial investment, realizing the all-round coverage of the medical and health industry chain.
In the capital market, Sinopharm has achieved a sound listing layout. Sinopharm Co., Ltd. was listed on the Shanghai Stock Exchange in November 2002 (stock code: 600511), and the group was listed on the Hong Kong Exchanges and Clearing Limited in September 2009 (stock code: 01099.HK). In 2025, Sinopharm ranked 119th on the Fortune Global 500 list with an operating revenue of 91,485.7 million US dollars, and 33rd on the China Top 500 Enterprises list, demonstrating strong operational strength and industry influence.
In the international market, Sinopharm has actively expanded its business and its products are exported to various parts of the world. It has made remarkable contributions to global public health security. For example, its COVID - 19 vaccine has been approved for emergency use in many countries and regions in Asia, Africa, South America and Europe, and was granted emergency listing by the World Health Organization, providing strong support for the global fight against the pandemic. Meanwhile, through extensive international cooperation and exchanges, Sinopharm has continuously enhanced its international competitiveness, and is committed to promoting the development of the global medical and health industry and safeguarding the life and health of people around the world.
